November 26, 2021
Article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.
In line with the push for more comprehensive care, literature suggests that patients with multiple sclerosis benefit from physical therapy interventions to help manage disease symptoms.
Video
The assistant professor of neurology at Weill Cornell Medicine discussed his future aspirations to uncover more about the beneficial effects of anticoagulants in reducing recurrent stroke. [WATCH TIME: 3 minutes]
The Bruton tyrosine kinase inhibitor has been evaluated in 2 phase 3 trials, GEMINI 1 and GEMINI 2 (NCT04410978; NCT04410991), in patients with relapsing-remitting and relapsing secondary progressive MS.
November 25, 2021
In a NeurologyLive® Insights series, experts in the diagnosis and treatment of Dravet syndrome discussed the management of the disease and the utilization of approved treatments to improve outcomes in patients.
In a NeurologyLive® Peer Exchange series, experts on the care of patients with multiple sclerosis offer recommendations for selecting and sequencing therapies used to treat patients with relapsing disease.
The director of the Comprehensive Epilepsy Center at NYU Langone provided closing thoughts on how clinicians can begin to shift gears from research to prevention of SUDEP. [WATCH TIME: 2 minutes]
The field of MS is shifting focus to issues such as understanding and tracking disease progression, approaches to treatment initiation, and the roles of diet and exercise in pathogenesis and disease course.
November 24, 2021
Aducanumab’s (Aduhelm; Biogen) $56,000 price point reflects the larger challenges of the United States’ insurance system and incites a cyclical series of events that have repercussions on cost of future therapies, state budgets, and legislative decisions.
The medical director of the Jefferson Sleep Disorders Center at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health offered his insight into the current state of care for sleep and the progress made this year.
